Researchers from Ruhr University Bochum and Heidelberg University have identified bemnifosbuvir, a nucleotide analogue currently in clinical trials for hepatitis C, as a promising candidate for treating hepatitis E. This discovery is particularly significant given the lack of approved treatments for hepatitis E, which is responsible for approximately 70,000 deaths annually. The study, published in Gut, highlights bemnifosbuvir’s ability to inhibit viral replication without damaging healthy tissue, marking a potential breakthrough in the management of this globally under-addressed viral infection.

The mechanism of action involves bemnifosbuvir mimicking the building blocks of genetic material, effectively disrupting the viral replication machinery of hepatitis E virus (HEV). In vitro tests demonstrated that cells treated with bemnifosbuvir showed no viral replication while maintaining cellular health. Subsequent animal studies corroborated these findings, revealing reduced viral activity and liver inflammation. This dual efficacy not only underscores the drug’s potential therapeutic value but also suggests a pathway for rapid repurposing, should ongoing hepatitis C trials yield positive results.

The implications of this research extend beyond immediate treatment options. If bemnifosbuvir is successfully repurposed for hepatitis E, it could catalyze a shift in how antiviral therapies are developed for neglected viral diseases. This could accelerate timelines for bringing effective treatments to market and prompt further exploration into the use of existing antiviral compounds against other under-researched pathogens. The collaboration between international research teams also highlights the importance of cross-border scientific efforts in addressing global health challenges.

Source: sciencedaily.com